<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01200615</url>
  </required_header>
  <id_info>
    <org_study_id>025622648</org_study_id>
    <nct_id>NCT01200615</nct_id>
  </id_info>
  <brief_title>The Nocebo Effect: a Prospective Study of Informed Consent as a Factor in the Prevalence of SSRI's Side Effects</brief_title>
  <official_title>The Nocebo Effect: a Prospective Study of Informed Consent as a Factor in the Prevalence of SSRI's Side Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we invetigate the influence of the nocebo effect (as part of obtaining informed&#xD;
      consent) on the prevalence of side-effects. The study is prospective, focusing on the&#xD;
      connection between what the physicians says to the patient about side-effects to the&#xD;
      frequency of these side effects during treatment period. We also inquire whether informing&#xD;
      the patient about the existence of the nocebo effect influences the extent of phenomena.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators wish to inquire whether the nature of the explenation given&#xD;
      to the patient as part of informed consent has an effect on the prevalence of side-effects.&#xD;
      The study will take place in the out-patient clinic at the Shalvata Mental health Center.&#xD;
      Three arms are included:&#xD;
&#xD;
        1. 50 patients started on SSRI's will be updated about its common side effects&#xD;
&#xD;
        2. 50 patients started on SSRI's will be updated about its common side effects and will&#xD;
           receive an explenation on the nocebo effect&#xD;
&#xD;
        3. 50 patients started on SSRI's will receive an explenation on the nocebo effect, but will&#xD;
           not be updated about common side-effects. Nonetheless, they will be informed of severe&#xD;
           side-effects.&#xD;
&#xD;
      Following the prescription of an SSRI the subjects will we enter the follow-up phase of the&#xD;
      study. They will attend two follow-up meetings: 3 days after the initiation point and one&#xD;
      month after the starting point. During each meeting they will be asked to fill the&#xD;
      Antidepressant Side-Effect Checklist (ASEC)and the General Health Questionnaire (GHQ).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The prevalence of side-effects</measure>
    <time_frame>6 weeks</time_frame>
    <description>We are interested in the possible influence of the physicians wording upon recieving informed consend from the patient and the prevalence of side-effects</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Explanation about common side effects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>50 patients started on SSRI's will be updated about its common side effects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Explaning side effects and the nocebo effect</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>subjects started on SSRI's will be updated about its common side effects and the nocebo effect</description>
  </arm_group>
  <arm_group>
    <arm_group_label>explanation about the nocebo effect</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3. 50 patients started on SSRI's will receive an explenation on the nocebo effect, but will not be updated about common side-effects. Nonetheless, they will be informed of severe side-effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Wording of the explenation on side-effects as part of the informed consent.</intervention_name>
    <description>Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.</description>
    <arm_group_label>Explanation about common side effects</arm_group_label>
    <arm_group_label>Explaning side effects and the nocebo effect</arm_group_label>
    <arm_group_label>explanation about the nocebo effect</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age 18-60&#xD;
&#xD;
          2. started on an SSRI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychotic spectrum disorder&#xD;
&#xD;
          -  Suicidality&#xD;
&#xD;
          -  Sensitivity to SSRI&#xD;
&#xD;
          -  Has taken the prescribed SSRI in the past&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uri Nitzan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shalvata Mental Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shalvata Mental Health Center</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>August 26, 2010</study_first_submitted>
  <study_first_submitted_qc>September 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <last_update_submitted>September 10, 2010</last_update_submitted>
  <last_update_submitted_qc>September 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Uri Nitzan</name_title>
    <organization>Shalvata Mental Health Center</organization>
  </responsible_party>
  <keyword>nocebo side-effects SSRI informed consent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

